828 WINTER STREET, WALTHAM, MA
Financial Results, Press Release
Announces 1-for-14 Reverse Stock Split
Investor Presentation
Stockholders Approve Reverse Stock Split Proposal at Special Meeting
Announces Pricing of Underwritten Offering
Highlights Upcoming Milestones and Recent Corporate Updates
Xilio Therapeutics Issues Series B and C Warrants; $35.8M Proceeds Received
Xilio Therapeutics Stockholders Approve 2025 Stock Incentive Plan
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload